Your browser doesn't support javascript.
loading
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2.
Gaynor, Katherine U; Vaysburd, Marina; Harman, Maximilian A J; Albecka, Anna; Jeffrey, Phillip; Beswick, Paul; Papa, Guido; Chen, Liuhong; Mallery, Donna; McGuinness, Brian; Van Rietschoten, Katerine; Stanway, Steven; Brear, Paul; Lulla, Aleksei; Ciazynska, Katarzyna; Chang, Veronica T; Sharp, Jo; Neary, Megan; Box, Helen; Herriott, Jo; Kijak, Edyta; Tatham, Lee; Bentley, Eleanor G; Sharma, Parul; Kirby, Adam; Han, Ximeng; Stewart, James P; Owen, Andrew; Briggs, John A G; Hyvönen, Marko; Skynner, Michael J; James, Leo C.
Affiliation
  • Gaynor KU; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Vaysburd M; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
  • Harman MAJ; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Albecka A; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
  • Jeffrey P; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Beswick P; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Papa G; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
  • Chen L; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Mallery D; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
  • McGuinness B; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Van Rietschoten K; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Stanway S; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.
  • Brear P; Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, United Kingdom.
  • Lulla A; Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, United Kingdom.
  • Ciazynska K; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
  • Chang VT; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
  • Sharp J; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Neary M; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Box H; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Herriott J; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Kijak E; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Tatham L; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Bentley EG; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Sharma P; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Kirby A; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Han X; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Stewart JP; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Owen A; University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.
  • Briggs JAG; MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
  • Hyvönen M; Max Planck Institute of Biochemistry, Martinsried, 82152, Germany.
  • Skynner MJ; Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, United Kingdom.
  • James LC; Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom. michael.skynner@bicycletx.com.
Nat Commun ; 14(1): 3583, 2023 06 16.
Article de En | MEDLINE | ID: mdl-37328472
ABSTRACT
COVID-19 has stimulated the rapid development of new antibody and small molecule therapeutics to inhibit SARS-CoV-2 infection. Here we describe a third antiviral modality that combines the drug-like advantages of both. Bicycles are entropically constrained peptides stabilized by a central chemical scaffold into a bi-cyclic structure. Rapid screening of diverse bacteriophage libraries against SARS-CoV-2 Spike yielded unique Bicycle binders across the entire protein. Exploiting Bicycles' inherent chemical combinability, we converted early micromolar hits into nanomolar viral inhibitors through simple multimerization. We also show how combining Bicycles against different epitopes into a single biparatopic agent allows Spike from diverse variants of concern (VoC) to be targeted (Alpha, Beta, Delta and Omicron). Finally, we demonstrate in both male hACE2-transgenic mice and Syrian golden hamsters that both multimerized and biparatopic Bicycles reduce viraemia and prevent host inflammation. These results introduce Bicycles as a potential antiviral modality to tackle new and rapidly evolving viruses.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: SARS-CoV-2 / COVID-19 Limites: Animals Langue: En Journal: Nat Commun Sujet du journal: BIOLOGIA / CIENCIA Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: SARS-CoV-2 / COVID-19 Limites: Animals Langue: En Journal: Nat Commun Sujet du journal: BIOLOGIA / CIENCIA Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni
...